- Trials with a EudraCT protocol (78)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (4)
78 result(s) found for: Von Willebrand disease.
Displaying page 1 of 4.
EudraCT Number: 2008-004922-18 | Sponsor Protocol Number: CSLCT-BIO-08-54 | Start Date*: 2009-04-16 | ||||||||||||||||
Sponsor Name:CSL Behring GmbH | ||||||||||||||||||
Full Title: An Open-label, Multi-centre Study to Assess the Pharmacokinetics, Efficacy and Safety of Biostate® in Subjects with Von Willebrand Disease. | ||||||||||||||||||
Medical condition: Von Willebrand Disease | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adolescents, Under 18, Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: BG (Completed) | ||||||||||||||||||
Trial results: View results |
EudraCT Number: 2012-003450-92 | Sponsor Protocol Number: IG1005 | Start Date*: 2013-11-23 | |||||||||||||||||||||
Sponsor Name:Instituto Grifols S.A. | |||||||||||||||||||||||
Full Title: EVALUATION OF THE PHARMACOKINETIC PROFILE, CLINICAL EFFICACY AND SAFETY OF THE VON WILLEBRAND FACTOR CONTAINED IN FANHDI® (DOUBLE-INACTIVATED HUMAN ANTI-HEMOPHILIC FACTOR) IN PEDIATRIC PATIENTS WIT... | |||||||||||||||||||||||
Medical condition: Severe von Willebrand disease including types I, II, and III with VWF:RCof <15-20% | |||||||||||||||||||||||
|
|||||||||||||||||||||||
Population Age: Infants and toddlers, Children, Under 18 | Gender: Male, Female | ||||||||||||||||||||||
Trial protocol: ES (Ongoing) | |||||||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2007-004116-32 | Sponsor Protocol Number: Protocol WIL1-0609 | Start Date*: 2008-12-03 | |||||||||||
Sponsor Name:LFB BIOTECHNOLOGIES | |||||||||||||
Full Title: EFFICACY AND SAFETY STUDY OF WILFACTIN ADMINISTERED BY CONTINUOUS INFUSION IN PATIENTS WITH SEVERE VON WILLEBRAND DISEASE UNDERGOING MAJOR SURGICAL PROCEDURES | |||||||||||||
Medical condition: Severe von Willebrand disease patients undergoing elective major surgery | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: FR (Completed) BE (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2005-001426-84 | Sponsor Protocol Number: WIL-14 | Start Date*: 2006-02-09 | |||||||||||
Sponsor Name:Octapharma AG | |||||||||||||
Full Title: CLINICAL STUDY TO INVESTIGATE THE EFFICACY, SAFETY AND IMMUNOGENICITY OF WILATE IN CHILDREN < 6 YEARS OF AGE WITH INHERITED VON WILLEBRAND DISEASE | |||||||||||||
Medical condition: Inherited von Willebrand Disease | |||||||||||||
|
|||||||||||||
Population Age: Infants and toddlers, Children, Under 18 | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) FR (Completed) CZ (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2005-001746-17 | Sponsor Protocol Number: 42-73-406/ WIL1-0406 | Start Date*: 2005-04-13 | |||||||||||
Sponsor Name:LFB BIOTECHNOLOGIES | |||||||||||||
Full Title: EFFICACY AND SAFETY STUDY OF vWF SD-35-DH (WILFACTIN) IN PATIENTS UNDER LONG TERM PROPHYLAXIS | |||||||||||||
Medical condition: von Willebrand disease | |||||||||||||
|
|||||||||||||
Population Age: Children, Adolescents, Under 18, Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: BE (Completed) PL (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2023-000044-34 | Sponsor Protocol Number: BT200-VWD2B | Start Date*: 2024-08-14 | |||||||||||
Sponsor Name:Medical University of Vienna, Department of Clinical Pharmacology | |||||||||||||
Full Title: Efficacy and Safety of BT200 (rondoraptivon pegol) in Patients with Type 2B von Willebrand disease | |||||||||||||
Medical condition: patients with type 2B Von Willebrand Disease with thrombocytopenia | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: AT (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2014-005401-20 | Sponsor Protocol Number: CSLCT-BIO-03-97 | Start Date*: 2015-01-30 | |||||||||||
Sponsor Name:CSL Limited | |||||||||||||
Full Title: An Open-label, Multi-centre Study to Assess the Efficacy and Safety of Biostate® in Patients With von Willebrand's Disease (VWD) | |||||||||||||
Medical condition: Von Willebrand's disease (VWD) | |||||||||||||
|
|||||||||||||
Population Age: Children, Under 18 | Gender: Male, Female | ||||||||||||
Trial protocol: Outside EU/EEA | |||||||||||||
Trial results: View results |
EudraCT Number: 2008-001910-25 | Sponsor Protocol Number: WIL-21 | Start Date*: 2008-07-17 | |||||||||||
Sponsor Name:Octapharma AG | |||||||||||||
Full Title: Pharmacokinetics of WILATE® and Haemate® P in von Willebrand type 3 patients - a prospective, randomised, controlled, open-labelled, 2-arm cross-over study | |||||||||||||
Medical condition: Inherited von Willebrand Disease (VWD) type 3 | |||||||||||||
|
|||||||||||||
Population Age: Adolescents, Under 18, Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: SK (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2004-005051-34 | Sponsor Protocol Number: 42-73-305 / WIL1-0305 | Start Date*: 2005-04-18 | |||||||||||
Sponsor Name:LFB BIOTECHNOLOGIES | |||||||||||||
Full Title: Efficacy and safety study of vWF SD-35-DH (WILFACTIN) in children under 6 years of age | |||||||||||||
Medical condition: Von Willebrand disease | |||||||||||||
|
|||||||||||||
Population Age: Newborns, Infants and toddlers, Children, Under 18 | Gender: Male, Female | ||||||||||||
Trial protocol: BE (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2013-003305-25 | Sponsor Protocol Number: CSLCT-BIO-12-83 | Start Date*: 2015-07-07 | |||||||||||
Sponsor Name:CSL Behring GmbH | |||||||||||||
Full Title: An Open-label, Multi-centre Post-marketing Study to Assess the Efficacy and Safety of Voncento® in Subjects with Von Willebrand Disease | |||||||||||||
Medical condition: Von Willebrand Disease | |||||||||||||
|
|||||||||||||
Population Age: Infants and toddlers, Children, Adolescents, Under 18, Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (Completed) DE (Completed) AT (Completed) IE (Completed) PL (Completed) GR (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2010-024108-84 | Sponsor Protocol Number: 071001 | Start Date*: 2011-10-31 | |||||||||||
Sponsor Name:Baxter Innovations GmbH | |||||||||||||
Full Title: A PHASE 3 CLINICAL STUDY TO DETERMINE THE PHARMACOKINETICS, SAFETY AND EFFICACY OF rVWF:rFVIII and rVWF IN THE TREATMENT OF BLEEDING EPISODES IN SUBJECTS DIAGNOSED WITH VON WILLEBRAND DISEASE | |||||||||||||
Medical condition: Von Willebrand Disease | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: GB (Completed) DE (Completed) SE (Completed) AT (Completed) NL (Completed) BE (Completed) BG (Completed) IT (Completed) ES (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2016-001478-14 | Sponsor Protocol Number: 071301 | Start Date*: Information not available in EudraCT | ||||||||||||||||
Sponsor Name:Baxalta Innovations GmbH | ||||||||||||||||||
Full Title: A PROSPECTIVE, PHASE 3, OPEN LABEL, INTERNATIONAL MULTICENTER STUDY ON EFFICACY AND SAFETY OF PROPHYLAXIS WITH rVWF IN SEVERE VON WILLEBRAND DISEASE | ||||||||||||||||||
Medical condition: Hereditary severe von Willebrand Disease | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: GB (Completed) IT (Completed) CZ (Completed) NL (Completed) ES (Completed) DE (Completed) FI (Completed) FR (Completed) | ||||||||||||||||||
Trial results: View results |
EudraCT Number: 2006-000664-85 | Sponsor Protocol Number: 8VWF03 | Start Date*: 2006-12-19 |
Sponsor Name:Bio Products Laboratory | ||
Full Title: An Open Multi-centre Study to Investigate the Safety and Efficacy of OPTIVATE®, a High Purity, Dual Inactivated Factor VIII and von Willebrand Factor Concentrate, in Patients with von Willebrand Di... | ||
Medical condition: von Willebrand disease | ||
Disease: | ||
Population Age: Adolescents, Under 18, Adults, Elderly | Gender: Male, Female | |
Trial protocol: GB (Completed) PL (Ongoing) | ||
Trial results: (No results available) |
EudraCT Number: 2010-021162-30 | Sponsor Protocol Number: Wil-24 | Start Date*: 2011-12-20 | |||||||||||
Sponsor Name:Octapharma AG | |||||||||||||
Full Title: Prospective, Open-Label, Multi-Center, Phase III Clinical Study To Investigate The Efficacy And Safety Of Human Factor VWF/VIII Concentrate (Wilate®) In Subjects With Inherited Von Willebrand Disea... | |||||||||||||
Medical condition: Surgery in Inherited Von Willebrand Disease (VWD) | |||||||||||||
|
|||||||||||||
Population Age: Children, Adolescents, Under 18, Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: BG (Completed) IT (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2009-017753-34 | Sponsor Protocol Number: CSLCT-BIO-08-52 | Start Date*: 2010-07-09 | |||||||||||
Sponsor Name:CSL Behring GmbH | |||||||||||||
Full Title: A Phase III Open-label, Multi-centre Study to Assess the Pharmacokinetics, Efficacy, and Safety of Biostate® in Paediatric Subjects with von Willebrand Disease. | |||||||||||||
Medical condition: Von Willebrand Disease | |||||||||||||
|
|||||||||||||
Population Age: Newborns, Infants and toddlers, Children, Under 18 | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) BG (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2004-004868-69 | Sponsor Protocol Number: AP7000_1-4002 | Start Date*: 2005-03-07 | |||||||||||
Sponsor Name:ZLB Behring LLC | |||||||||||||
Full Title: Study of Safety and Efficacy of Antihemophilic Factor / von Willebrand Factor Complex (Humate-P®) Using Individualized Dosing in Pediatric and Adult Surgical Subjects with von Willebrand’s Disease | |||||||||||||
Medical condition: Von Willebrand’s disease (VWD) is a common hereditary bleeding disorder. The impaired formation and adhesion of the initial platelet plug is reflected in the prolonged skin bleeding time. In addit... | |||||||||||||
|
|||||||||||||
Population Age: Newborns, Infants and toddlers, Children, Adolescents, Under 18, Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: AT (Completed) SE (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2006-000663-28 | Sponsor Protocol Number: 8VWF01 | Start Date*: Information not available in EudraCT | |||||||||||
Sponsor Name:Bio Products Laboratory | |||||||||||||
Full Title: An open multi-centre study in patients with von Willebrand Disease to investigate the pharmacokinetics, efficacy and safety of Optivate, a high purity, dual inactivated Factor VIII and Von Willebra... | |||||||||||||
Medical condition: von Willebrands Disease | |||||||||||||
|
|||||||||||||
Population Age: Adolescents, Under 18, Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: PL (Ongoing) GB (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2009-017301-11 | Sponsor Protocol Number: CSLCT-BIO-09-64 | Start Date*: 2010-09-20 | |||||||||||
Sponsor Name:CSL Behring GmbH | |||||||||||||
Full Title: An Open-Label, Multi-Centre Extension Study to Assess the Efficacy and Safety of Biostate® in Paediatric, Adolescent, and Adult Subjects with Von Willebrand Disease who Completed Clinical Studies C... | |||||||||||||
Medical condition: Von Willebrand's Disease | |||||||||||||
|
|||||||||||||
Population Age: Newborns, Infants and toddlers, Children, Adolescents, Under 18, Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: BG (Completed) PL (Completed) DE (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2006-001383-23 | Sponsor Protocol Number: PROWILL | Start Date*: 2006-06-30 | |||||||||||
Sponsor Name:FONDAZIONE CENTRO EMOFILIA E TROMBOSI ANGELO BIANCHI BONOMI | |||||||||||||
Full Title: Efficacy, safety and pharmaco-economic assessment of secondary long term prophylaxis with highly purified, standardized, doubly virus inactivated FVIII/VWF concentrates in patients with severe, inh... | |||||||||||||
Medical condition: patients with severe inherited VWD unresponsive to DDAVP and with frequent bleedings | |||||||||||||
|
|||||||||||||
Population Age: Newborns, Infants and toddlers, Children, Adolescents, Under 18, Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: IT (Completed) GB (Completed) ES (Completed) DE (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2014-003575-38 | Sponsor Protocol Number: 071101 | Start Date*: 2015-01-07 | |||||||||||
Sponsor Name:Baxalta Innovations GmbH | |||||||||||||
Full Title: A PHASE 3 PROSPECTIVE, MULTICENTER STUDY TO EVALUATE EFFICACY AND SAFETY OF rVWF WITH OR WITHOUT ADVATE IN ELECTIVE SURGICAL PROCEDURES IN SUBJECTS WITH SEVERE VON WILLEBRAND DISEASE | |||||||||||||
Medical condition: Hereditary severe von Willebrand Disease in adult patients who will undergo major and minor elective surgical procedures | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: AT (Completed) IT (Completed) CZ (Completed) GB (Completed) NL (Completed) ES (Completed) DE (Completed) | |||||||||||||
Trial results: View results |
Subscribe to this Search
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here

Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
